Eine Kamera ist auf eine reflektierende Glasscheibe gerichtet.
© DZIF

News

All current DZIF news can be found here.

Blurred net-like structures are visible on a blue background. The nodes of the net structure are coloured red. The logo of the DZIF Academy is shown at the top left and the icon of a certificate can be seen on the right of the image.
© hunthomas/Adobe Stock

Apply now: DZIF Prize for Translational Infection Research 2023

The German Center for Infection Research (DZIF) is again offering the DZIF Prize for Translational Infection Research. Scientists can apply to the DZIF Academy until 15 August 2023. A prize of 5,000

Coronavirus
© Fusion Medical Animation

Infection with common cold coronaviruses can trigger broad cross-immunity against SARS-CoV-2 proteins

Researchers at the University Medical Center Hamburg-Eppendorf have demonstrated cross-reactive immune responses to another SARS-CoV-2 protein besides the spike protein. The research team found a

Incate
© INCATE

European initiative INCATE: Phase II funding of a start-up for the development of antimicrobial proteins

The incubator INCATE (INCubator for Antibacterial Therapies in Europe) was founded by a consortium of academic institutions—including the German Center for Infection Research (DZIF)—and industrial

Schematic representation of two agar plates, each with a paper strip. On the left plate, an inhibition zone can be seen around the paper strip.
© Frantz R. et al., 2023/Renate Frantz

Targeting resistance to a crucial reserve antibiotic

Colistin is a last-line reserve antibiotic for the treatment of infections caused by extremely multidrug-resistant (XDR) Gram-negative bacteria. The recent emergence and global spread of the mobile

Victoria Ingham in the lab holding a suction flask full of Anopheles mosquitoes.
© Heidelberg University Hospital

DZIF malaria researcher gains funding

Dr. Victoria Ingham from Heidelberg University Hospital and the German Center for Infection Research (DZIF) is investigating the potential dual effect of a new insecticide for mosquito nets. The

Electron micrograph of a cluster of rod-shaped bacterial cells in gray. 
© Universität Greifswald/Nicole Metzendorf, Rabea Schlüter 

New drug candidate found against persistent intestinal pathogens

Infections with the bacterium Clostridioides difficile (C. difficile for short) frequently recur due to permanent stages remaining in the intestine. A drug that also effectively combats the permanent

Electron micrograph of two H. pylori cells in yellow binding to human gastric epithelial cells (stained red below).
© Max von Pettenkofer-Institut der LMU/Rainer Haas

Targeting Helicobacter: nipping stomach cancer in the bud

The pathogen Helicobacter pylori, which is responsible for highly prevalent diseases such as gastric ulcers or cancer, has a weak spot that could be used to produce new drugs. This was discovered by a

The background shows an abstract wave-like light to dark green structure. At the top left of the picture, a segment of an oval can be seen, on which the logo and the subtitle of the project can be seen: eWHORM, Eliminating Worm Infections in Sub-Saharan Africa. The "e" of the logo is formed by a green worm (filaria) in the shape of an "e".
© eWHORM

Launch of the EU-funded project eWHORM – enabling the WHO Road Map: Eliminate worm infections in Sub-Saharan Africa

African and European partners join forces to enable the World Health Organisation’s (WHO) “Road Map for Neglected Tropical Diseases” (NTDs) and reduce the burden of disease associated with worm

The company logo with the words EBViously on top of a schematic virus particle is placed on a background of blue coloured cells and several green coloured virus particles.
© CDC/Dr. Paul M Feorino; DZIF/EBViously

DZIF-project-derived start-up “EBViously“ announces first details of its EBV vaccine candidate

EBViously, a spin-off from Helmholtz Munich (HMGU), is led by world-leading experts in Epstein-Barr virus biology, genetics, and immunity and was founded to develop a safe and highly effective

Portray of Prof Rolf Hilgenfeld, Universität zu Lübeck
© Universität zu Lübeck/Thomas Berg

Carl-Hermann-Medal awarded to Rolf Hilgenfeld

The German Society for Crystallography has awarded the Carl-Hermann-Medal to the biochemist Prof. Rolf Hilgenfeld. The award honours the scientific life of outstanding research personalities in the